Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
SLC7A11 encodes a member of a heteromeric, sodium-independent, anionic amino acid transport system that is highly specific for cysteine and glutamate. Additionally we are shipping SLC7A11 Kits (18) and SLC7A11 Proteins (5) and many more products for this protein.
Showing 10 out of 101 products:
Human Polyclonal SLC7A11 Primary Antibody for FACS, ICC - ABIN152648
Liu, Blower, Pham, Fang, Dai, Wise, Green, Teitel, Ning, Ling, Lyn-Cook, Kadlubar, Sadée, Huang: Cystine-glutamate transporter SLC7A11 mediates resistance to geldanamycin but not to 17-(allylamino)-17-demethoxygeldanamycin. in Molecular pharmacology 2007
Show all 40 Pubmed References
Human Polyclonal SLC7A11 Primary Antibody for ICC, IF - ABIN152647
Pampliega, Domercq, Soria, Villoslada, Rodríguez-Antigüedad, Matute: Increased expression of cystine/glutamate antiporter in multiple sclerosis. in Journal of neuroinflammation 2011
Show all 4 Pubmed References
Mouse (Murine) Polyclonal SLC7A11 Primary Antibody for IHC - ABIN967037
Sato, Tamba, Ishii, Bannai: Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. in The Journal of biological chemistry 1999
Show all 3 Pubmed References
Human Polyclonal SLC7A11 Primary Antibody for IHC (p) - ABIN2477153
Choné, Menges, Wurster: [Leiomyoma of the esophagus with an epiphrenal diverticulum]. in RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 1978
Show all 3 Pubmed References
Human Polyclonal SLC7A11 Primary Antibody for ELISA, WB - ABIN252942
Zhang, Trachootham, Liu, Chen, Pelicano, Garcia-Prieto, Lu, Burger, Croce, Plunkett, Keating, Huang: Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. in Nature cell biology 2012
Show all 2 Pubmed References
System xC(-)-mediated TrkA (show NTRK1 Antibodies) activation therefore presents a promising target for therapeutic intervention in cancer pain treatment.
High expression of cystine-glutamate (show GRIN1 Antibodies) antiporter SLC7A11 is associated with advanced pathological stages of liver carcinoma. SLC7A11 overexpression is a novel biomarker and a potential unfavorable prognostic factor as well as a potential therapeutic target for liver carcinoma.
the level of antisense SLC7A11 was markedly reduced in epithelial ovarian cancer tissues and cell lines compared with those of normal control; reduction of antisense SLC7A11 level prompted ovarian cancer cell migration mainly by suppressing the expression of SLC7A11
CD44v9 in tumor specimens has potential as a novel indicator for identifying a cisplatin-chemoresistant population among urothelial cancer patients. CD44v8-10 contributes to reactive oxygen species defenses, which are involved in chemoresistance, by promoting the function of xCT, which adjusts the synthesis of glutathione.
Oncogenic PIK3CA (show PIK3CA Antibodies) alters methionine and cysteine utilization, partly by inhibiting xCT to contribute to the methionine dependency phenotype in human breast cancer cells.
these observations suggest that SLC7A11 may be a vital biomarker for the diagnosis and prognosis in human laryngeal squamous cell carcinoma (LSCC) and targeting SLC7A11 appears to be a potentially significant method for LSCC treatment.
Aberrant neuronal or neuroendocrine system may be involved in the suppressed reproductive performance in xCT deficient male mice.
overexpression of SLC7A11 in the context of glioblastoma multiforme may contribute to tumor progression.
miR (show MLXIP Antibodies)-375 served as a tumor suppressor via regulating SLC7A11.
As targets of oncogenes with intrinsic tyrosine kinase (show TXK Antibodies) activity, STAT3 (show STAT3 Antibodies) and STAT5 (show STAT5A Antibodies) become constitutively active in hematologic neoplasms and solid tumors, promoting cell proliferation and survival and modulating redox homeostasis via regulation xCT expression. (Review)
In mouse brain parenchyma, xCT is selectively expressed in scattered astrocytes throughout the brain. Especially strong xCT labeling is found in select blood/brain/CSF (show CSF2 Antibodies) interface areas: in the leptomeninges, along larger blood vessels, in some circumventricular organs and in tanycytes in parts of the walls of the ventral third ventricle. Study did not find expression of xCT in microglia, oligodendrocytes and neurons.
Authors found that the xCT expression was increased in peripheral blood monocyte of active tuberculosis. xCT expression in macrophage was induced by Mycobacterium tuberculosis (Mtb (show NCAPG2 Antibodies)) through TLR2/Akt (show AKT1 Antibodies)- and p38 (show CRK Antibodies)-dependent signaling pathway.
Protein expression of xCT is enhanced in immune cells from an animal model of multiple sclerosis.
Study suggests that mature astrocytes have low expression levels of xCT and that they do not depend on its function to survive. In contrast, oligodendrocytes, which express high levels of xCT, are the most vulnerable cell type of CNS to glutathione depletion upon chronic blockage of xCT or under oxidative glutamate (show GRIN1 Antibodies) toxicity.
ARF inhibits tumor growth by suppressing the ability of NRF2 (show NFE2L2 Antibodies) to transcriptionally activate its target genes, including SLC7A11, a component of the cystine/glutamate (show GRIN1 Antibodies) antiporter that regulates reactive oxygen species (ROS (show ROS1 Antibodies))-induced ferroptosis.
Expression of xCT is reduced in astroglia in a genetic mouse model of susceptibility to depressive-like behavior.
Data suggest that glucose starvation of various neoplasm cell lines induces Slc7a11 expression; Slc7a11 overexpression decreases intracellular glutamate (show GRIN1 Antibodies), an alternative source of metabolic energy; provision of alpha-ketoglutarate, a key downstream metabolite of glutamate (show GRIN1 Antibodies), restores survival in Slc7a11-overexpressing neoplasm cell lines under glucose starvation.
HIF-1alpha (show HIF1A Antibodies) plays a role in cerebral ischaemia-reperfusion -induced glutamate (show GRIN1 Antibodies) excitotoxicity via the long-lasting activation of system xc(-) -dependent glutamate (show GRIN1 Antibodies) outflow
Results provided important insights into understanding the mechanism associated with xCT deficiency.
This gene encodes a member of a heteromeric, sodium-independent, anionic amino acid transport system that is highly specific for cysteine and glutamate. In this system, designated Xc(-), the anionic form of cysteine is transported in exchange for glutamate. This protein has been identified as the predominant mediator of Kaposi sarcoma-associated herpesvirus fusion and entry permissiveness into cells. Also, increased expression of this gene in primary gliomas (compared to normal brain tissue) was associated with increased glutamate secretion via the XCT channels, resulting in neuronal cell death.
solute carrier family 7, (cationic amino acid transporter, y+ system) member 11
, cystine/glutamate transporter
, solute carrier family 7, member 11
, Cystine/glutamate transporter
, cystine/glutamate transporter-like
, solute carrier family 7 (anionic amino acid transporter light chain, xc- system), member 11
, amino acid transport system xc-
, calcium channel blocker resistance protein CCBR1
, solute carrier family 7 member 11
, solute carrier family 7 (cationic amino acid transporter, y+ system), member 11
, cysteine/glutamate transporter
, sodium independent anionic amino acid transport system